预约演示

更新于：2025-02-28

Bevacizumab

贝伐珠单抗

更新于：2025-02-28

概要

基本信息

药物类型

单克隆抗体

别名

Bevacizumab(Genetical Recombination)、rhuMAb-VEGF、贝伐单抗

+ [17]

靶点

VEGF-A

作用机制

VEGF-A抑制剂(血管内皮生长因子A抑制剂)、血管生成抑制剂

治疗领域

肿瘤神经系统疾病消化系统疾病+ [12]

在研适应症

不可切除的肝细胞癌肝细胞癌复发性胶质母细胞瘤+ [203]

非在研适应症

异戊酸血症急性嗜碱性粒细胞白血病急性嗜酸细胞白血病+ [280]

原研机构

Genentech, Inc.

在研机构

National Cancer Institute

Genentech, Inc.

MedImmune LLC

+ [22]

非在研机构

Sanofi

Hoffmann-La Roche Ltd.

Celgene Corp.

+ [18]

最高研发阶段批准上市

首次获批日期

美国 (2004-02-26),

结肠癌直肠癌

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 41632H

来源: *****

Sequence Code 41637L

来源: *****

关联

3,096

项与贝伐珠单抗相关的临床试验

NCT06393751

/ Not yet recruiting临床1/2期IIT

A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

This phase I/II trial tests the safety, best dose and effectiveness of adding tolinapant (ASTX660) to paclitaxel with or without bevacizumab in treating patients with ovarian cancer that has come back after a period of improvement (recurrent). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells and increase resistance to chemotherapy. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of tumor cells. Adding ASTX660 to paclitaxel with or without bevacizumab may be safe, tolerable and/or effective in treating patients with recurrent ovarian cancer.

开始日期2025-05-02

申办/合作机构

National Cancer Institute

NCT06784947

/ Not yet recruiting临床2期IIT

A Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Previously Treated, Microsatellite Stable, Metastatic Colorectal Adenocarcinoma

The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are:
1. Does the study treatment effectively treat colorectal cancer?
2. Is the study treatment safe for patients with colorectal cancer?
3. How does the study treatment effect the immune system in patients with colorectal cancer?
Participants in this study will receive the study treatment and undergo checkups, laboratory tests, and imaging tests for monitoring. Some participants will also undergo tumor biopsies.

开始日期2025-05-01

申办/合作机构

University of Colorado Denver

[+1]

NCT06607458

/ Not yet recruiting临床2期

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients with Refractory Metastatic Colorectal Cancer with Liver Dominant Disease

The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone.
Participants will:
* Undergo up to two liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone
* Visit clinic at least every two weeks for checkups and tests
* Complete scans approximately every two months

开始日期2025-05-01

申办/合作机构

Delcath Systems, Inc.

100 项与贝伐珠单抗相关的临床结果

登录后查看更多信息

100 项与贝伐珠单抗相关的转化医学

登录后查看更多信息

100 项与贝伐珠单抗相关的专利（医药）

登录后查看更多信息

22,453

项与贝伐珠单抗相关的文献（医药）

2025-12-01·Journal of Gastrointestinal Cancer

Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer

Article

作者: Gou, Miaomiao ; Qian, Niansong ; Dai, Guanghai ; Zhang, Yong ; Wang, Zhikuan

BACKGROUND:

The survival benefit from later-line treatment for patients with metastatic colorectal cancer (mCRC) remains disappointing. Here, in a real-world study, we were aimed to evaluate which choice will affect the survival of mCRC patients after standard treatment in Chinese patients.

METHODS:

A total of 129 patients with refractory mCRC were involved in the study. They received targeted monotherapy or combined with chemo-agents or PD-1 inhibitor before death. Overall survival (OS) and progression-free survival (PFS) were reviewed and evaluated from clinical features and treatment options.

RESULTS:

Among the 129 patients, the median age was 56 years (25-81). The mOS from third-line was 12.5 months. OS of patients who treated with chemo plus targeted therapy group in third-line was shown to be superior to pd-1 inhibitor in combination with antiangiogenic agents or antiangiogenic monotherapy group (15.6 m vs. 10.5 m vs. 8.4 m, p < 0.05). Patients had received triplet-drugs (bevacizumab plus low-dose irinotecan and oxaliplatin) and had prolonged survival compared to those had not (21.3 m vs 10.3 m, p = 0.004). OS between patients who had immunotherapy history or not was not significantly different (p > 0.05). The mPFS was 3.5 months in patients who had administered with antiangiogenic targeted agents plus anti-pd-1 and 4.7 months in chemo plus targeted therapy group and 2.2 months in the other group. In the triplet drugs group, preliminary results showed that ORR was 13.3% and DCR was 80%. The median PFS was 5.1 m, and the median OS was 10.6 m.

CONCLUSIONS:

Triplet drugs resulted in significantly longer overall survival, and immunotherapy may have limited benefit in MSS type CRC patients.

2025-11-01·Current diabetes reviews

Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview

Article

作者: Khandelwal, Aman ; Ponnusankar, S. ; Nirmal, Jayabalan ; Gowthamarajan, Kuppusamy

The discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-care treatment for a range of ocular ailments and improved patients' clinical results with diabetic retinopathy and Diabetic Macular Edema, and their frequency has grown exponentially with the introduction of these agents Pegaptanib, Ranibizumab, and Aflibercept which are approved for ophthalmic indications, while Bevacizumab is used off-label. These medications delivered intravitreally have halted the vascular development of diabetic retinopathy. Various randomized trials have proven that antivascular endothelial growth factor medication is safe and effective in preserving vision. Following an extensive period of preclinical development aimed at enhancing and defining its biological impacts, these drugs were shown in clinical trials to be effective in treating diabetic retinopathy and other ophthalmic conditions. Data from various sources suggest that Pegaptanib, Ranibizumab, and Aflibercept are costly, while Bevacizumab is cost-effective, and in low and middle-income nations, it is thus a desirable therapy choice. However, issues with compounding, counterfeiting, and off-label usage restrict its availability in many nations. The pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, and contraindications of antivascular endothelial growth factor agents are discussed, and the results of clinical trials evaluating their efficacy are summarized.

2025-04-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Optimization of immunotherapy-based combinations for metastatic renal cell carcinoma: A network meta-analysis

Review

作者: Park, Sohyeon ; Rhie, Sandy Jeong ; Park, Kalynn ; Kim, Chaeyoon

BACKGROUND:

Despite numerous meta-analyses comparing the efficacy and safety of immunotherapy-based combination therapies, the optimal therapeutic combinations remain unclear. This study aims to evaluate the optimal application of all immunotherapy-based combination therapy for advanced/metastatic renal cell carcinoma, focusing on efficacy and safety.

METHODS:

We systemically searched the Web of Science, Cochrane Library, and PubMed for studies regarding the first-line immunotherapy-based combination therapy in patients with advanced or metastatic renal cell carcinoma until April 15, 2024. We used network meta-analysis using a random effect model to facilitate direct and indirect treatment comparisons across outcomes.

RESULTS:

Seven clinical studies, including 5542 patients with metastatic renal cell carcinoma, were included in the network meta-analysis analysis. Regarding progression-free survival and overall survival, combined Toripalimab + Axitinib significantly outperformed other immunotherapy-based combination therapies. This regimen significantly improved progression-free survival in the intermediate/poor risk group when stratified by prognosis prediction risks compared to sunitinib alone. For the objective response rate, Avelumab + Axitinib was the most preferred strategy in the favorable-risk group, while Nivolumab + Cabozantinib was favored in the intermediate/poor-risk group compared to other immunotherapy-based combinations. The combinations of Nivolumab + Ipilimumab and Atezolizumab + Bevacizumab had favorable safety profiles.

CONCLUSIONS:

Immunotherapy-based combination therapies significantly improved progression-free survival, overall survival and objective response rate in patients with metastatic renal cell carcinoma compared to sunitinib monotherapy. However, careful monitoring and personalized treatment strategies are required to balance efficacy and safety in patients with underlying conditions. Future research should focus on optimizing treatment protocols and elucidating the mechanisms of adverse events.

3,027

项与贝伐珠单抗相关的新闻（医药）

2025-02-28

·PRNewswire

ACCESS MEDICAL LABS CONFIRMS ELIZABETH HOLMES EXACT PFIZER STUDY RESULTS USING THE SAME COMPONENTS

JUPITER, Fla., Feb. 28, 2025 /PRNewswire/ -- In a stunning revelation that will reshape the conversation around Elizabeth Holmes and her work at Theranos, one of the largest Specialty Labs in the Nation has confirmed that Holmes' diagnostic technology was in fact Accurate—and that her suppressed Test Result findings regarding Avastin®, a cancer drug were very accurate during the 15 month Pfizer study in 2007. In 2007 and 2008, Holmes conducted a study for Pfizer investigating the angiogenesis process and the effect of Bevacizumab, an anti-VEGF antibody therapy used in cancer treatment under the brand name, Avastin® See page 0012 of Trial exhibit 0143. – bottom half of 0012 shows the Avastin® affect. The Pfizer contract with Theranos was executed on December 12th 2006 worth $900,000.00. The study took place in clinics and in patient homes with her machine wirelessly transmitting Results to Theranos servers and the Pfizer portal during the course. Her research demonstrated that while the drug initially appeared to suppress VEGF levels, that was only true using another companies reagent that is used by LabCorp and many labs across the nation called, R&D Systems VEGF ELISA. Avastin® is a monoclonal antibody that attaches to VEGF in the body to prevent the body from making blood vessels (angiogenesis) so the cancer will not spread. The problem is, ELISA testing using Antibodies, in fact the same antibody as Avastin, Anti-VEGF or better known as Bevacizumab. This causes a problem when testing for VEGF because you cannot detect it due to the same antibody being present. It doesn't know VEGF is present, it is being blocked by Anti-VEGF. She also discovered that Avastin causes what's called a VEGF complex, which means the body starts creating TONS of VEGF. VEGF levels spiked dramatically—showing an alarming surge from an average of 140 pg/mL to over 8,000 pg/mL. This post-treatment VEGF REBOUND effect signals a rapid increase in blood vessel formation, which could exacerbate cancer proliferation rather than control it. Her study was also confirmed independently in 2023 by JAMA open network. Despite Holmes' findings, Pfizer and Dr. Shane Weber who testified against Elizabeth Holmes in court, rejected the results on December 31st 2008. Holmes' research was originally conducted using the Theranos Edison (TSPU - Theranos System Processing Unit), which ran proprietary assays to measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued. Holmes' Study was originally conducted using the Edison or aka the TSPU - Theranos Systems Processing Unit, which ran proprietary assays developed in house at Theranos and commercially available test kits used by Lab Giants, LabCorp and Quest. In this case of VEGF, she used her proprietary test measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued because she could detect the TOTAL VEGF. Today, Access Medical Labs has demonstrated that: Holmes' technology was indeed Accurate. Conventional testing methods, such as those used by LabCorp may underreport the true impact of anti-VEGF drugs. When Bevacizumab exits the bloodstream, a VEGF rebound may occur and CANNOT be detected early enough due to VEGF being blocked which could drastically increase the spread of cancer. Our lab testing proves that Elizabeth Holmes did not lie. Her tests & machine worked. Ryan ElHosseiny Access Medical Labs 954-494-1664 SOURCE Access Medical Labs WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果诊断试剂

2025-02-28

·Insight数据库

神州细胞 PD-1 单抗新适应症获批，用于肝细胞癌一线治疗

2 月 28 日，NMPA 官网显示，神州细胞菲诺利单抗和贝伐珠单抗（SCT510）的联合疗法申请获批上市。根据神州细胞公开资料，本次获批适应症为：用于既往未接受过系统治疗的不可切除或转移性肝细胞癌患者。图片来源：NMPA 官网菲诺利单抗（SCT-I10A）是神州细胞自主研发的重组人源化抗 PD-1 IgG4 型单克隆抗体，此前已在国内获批联合化疗用于治疗头颈部鳞状细胞癌，是首个获批治疗头颈部鳞癌的国产 PD-1 单抗。安贝珠（SCT510）是神州细胞开发的重组人源化抗 VEGF 单克隆抗体注射液，是贝伐珠单抗注射液（安维汀）的生物类似药。此前，安贝珠已获得 NMPA 批准用于治疗多种适应症，包括转移性结直肠癌、晚期/转移性或复发性非小细胞肺癌、复发性胶质母细胞瘤、肝细胞癌、宫颈癌，以及上皮性卵巢癌、输卵管癌或原发性腹膜癌。 2024 年 ASCO 年会上，神州细胞公布了在中国开展的一项开放标签、多中心、3 期试验(NCT04560894) 的中期分析数据。该研究评估了菲诺利单抗+贝伐珠单抗作为晚期肝细胞癌一线治疗的安全性和有效性，并与索拉非尼进行了比较。试验的两个共同主要终点是总生存期 (OS) 和无进展生存期 (PFS)。截至数据截止时间（2023 年 11 月 2 日），共有 346 名患者入组并接受至少一剂治疗，其中菲诺利单抗+贝伐珠单抗组入组 230 例患者，索拉非尼组入组 116 患者，中位随访时间为 19.7 个月。试验数据显示：菲诺利单抗+贝伐珠单抗组的中位 OS 为 22.1 个月，显著长于索拉非尼组的 14.2 个月（风险比 [HR] 0.60；95% 可信区间 [CI]：0.44，0.81；p=0.0008）。菲诺利单抗+贝伐珠单抗组的中位 PFS 为 7.1 个月，也显著长于索拉非尼组的 2.9 个月（HR 0.50；95%CI：0.38，0.65；p<0.0001）。菲诺利单抗+贝伐珠单抗组的客观缓解率（ORR）为 32.8%（75/229），而索拉非尼组的 ORR 只有 4.3%（5/116）。安全性方面，菲诺利单抗+贝伐珠单抗组 42.6% 的患者观察到≥3 级治疗相关不良事件 (TRAE)，索拉非尼组这一数值为 33.6% 。最常见的≥3 级 TRAE 是高血压。截图来源：Insight 数据库肝癌是常见的恶性肿瘤之一，肝细胞癌约占原发性肝癌的 75%-85%。大多数肝细胞癌患者在诊断时已是中晚期，预后差，五年生存率比较低，临床上存在着极大的未满足医疗需求。在很长时间内，索拉非尼一直是晚期肝细胞癌的标准治疗方案。近年来，随着免疫疗法在肿瘤领域的突破进展，晚期肝细胞癌患者也迎来了很多新的治疗方案。国内「晚期肝细胞癌一线治疗」在研药物竞争格局热力图截图来源：Insight 数据库 Insight 数据库显示，在晚期肝细胞癌一线赛道，目前国内已有 4 款「IO+贝伐珠单抗」方案处于获批或申报上市阶段。除了神州细胞的菲诺利单抗+贝伐珠单抗，罗氏的阿替利珠单抗+贝伐珠单抗、信达的信迪利单抗+贝伐珠单抗（IBI305）此前也已获批。此外，君实的特瑞普利单抗+贝伐珠单抗也已申报上市。 Insight 数据库「疾病竞争格局」模块临床数据显示，IO+贝伐珠单抗的 mPFS、mOS、ORR 都显著优于索拉非尼，已成为晚期肝细胞癌一线治疗的重要选择。国内「IO+贝伐珠单抗」方案治疗效果对比（仅展示NDA及以上阶段）截图来源：Insight 数据库 PS：Insight 数据库新上线的「疾病竞争格局」模块，可实现在同一个页面内清晰地展示、对比同一适应症的所有治疗方案间的疗效水平，快速识别 BIC 项目。如欲了解更多疾病的竞争格局，欢迎点击「阅读原文」试用。封面来源：企业 Logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

临床结果免疫疗法ASCO会议临床3期上市批准

2025-02-27

·ioncology

SGO 2025丨美国妇科肿瘤学年会上的中国好声音

点上方蓝字“ioncology”关注我们，然后点右上角“…”菜单，选择“设为星标” SGO 2025微专辑扫描二维码可查看更多内容第56届美国妇科肿瘤学年会（SGO 2025）将于2025年3月14-17日在西雅图举办。作为全球范围内最权威的妇科肿瘤学术会议之一，SGO年会将为业内同道提供交流最新研究成果和临床经验的平台，展示具有创新性及前沿视角的观点和思路。本文汇总中国学者在2025 SGO上的报告内容，如有疏漏，敬请指出。科学全体会议（Scientific Plenary）摘要ID：864114 英文标题：Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: a multicenter, single-arm, phase II trial 中文标题：卡度尼利单抗+乐伐替尼治疗晚期子宫内膜癌患者：一项多中心、单组I期试验汇报人：蓝春燕丨中山大学附属肿瘤医院摘要ID：812874 英文标题：Sentinel Lymph Node Biopsy versus Pelvic Lymphadenectomy in Cervical Cancer: the PHENIX-I trial 中文标题：宫颈癌前哨淋巴结活检vs盆腔淋巴结清扫术：PHENIX-I试验汇报人：刘继红丨中山大学肿瘤防治中心摘要ID：927707 英文标题：Comparing Efficacy and Safety of Biweekly Single-Dose Actinomycin D versus Multiday Methotrexate Therapy in Low-Risk Gestational Trophoblastic Neoplasia: A Prospective Multicentre Randomized Trial 中文标题：比较每两周单剂量放线菌素D vs多日甲氨蝶呤治疗低风险妊娠滋养细胞肿瘤的疗效和安全性：一项前瞻性多中心随机试验汇报人：蒋芳丨北京协和医院焦点论坛（Focused Forum）摘要ID：852145 英文标题：Zimberelimab plus lenvatinib in patients with advanced cervical cancer who progressed after prior immune checkpoint inhibitors: a multicenter, single-arm, phase II trial 中文标题：赛帕利单抗联合乐伐替尼治疗经免疫检查点抑制剂治疗后病情进展的晚期宫颈癌患者：一项多中心、单组、II期试验汇报人：蓝春燕丨中山大学附属肿瘤医院摘要ID：873424 英文标题：Immunotherapy Rechallenge with Cadonilimab in Patients with Recurrent or Metastatic Cervical Cancer: A Retrospective Study 中文标题：复发性或转移性宫颈癌患者再次接受卡度尼利单抗免疫疗法治疗：一项回顾性研究汇报人：Lin Jie丨福建省肿瘤医院摘要ID：937243 英文标题：Biomarker-driven Targeted Therapy in Platinum-Resistant Ovarian Cancer (PROC): Results from the BRIGHT Trial 中文标题：铂类耐药卵巢癌(PROC)的生物标志物驱动靶向治疗：BRIGHT试验结果汇报人：高庆蕾丨华中科技大学同济医学院附属同济医院摘要ID：838826 英文标题：(ENCORE) An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003) 中文标题：ENCORE：一项针对卡度尼利单抗联合新辅助化疗治疗晚期卵巢癌患者的开放标签、前瞻性II期研究（AK104-IIT-003）汇报人：唐洁丨湖南省肿瘤医院特色壁报专场（Featured Poster Session）摘要ID：823842 英文标题：AK104 combined with concurrent chemoradiotherapy for the treatment of locally advanced Cervical Cancer 中文标题：AK104联合同期放化疗治疗局部晚期宫颈癌汇报人：蒋芳丨北京协和医院摘要ID：823525 英文标题：Neoadjuvant Chemotherapy Followed by Chemoradiation Plus Adjuvant Chemotherapy for Locally Advanced Cervical Cancer: A Real-World Study with 10 Years Experience 中文标题：局部晚期宫颈癌患者在新辅助化疗后进行放化疗加辅助化疗：一项具有10年经验的真实世界研究汇报人：唐洁丨湖南省肿瘤医院摘要ID：859742 英文标题：Pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors: a multicenter, single-arm, phase Ib/II trial (POST-PARPi Trial) 中文标题：帕米帕利联合索凡替尼治疗经PARP抑制剂治疗的铂耐药性卵巢癌患者：一项多中心、单组、Ib/II期POST-PARPi试验汇报人：蓝春燕丨中山大学附属肿瘤医院壁报导览（Poster Tour）摘要ID：823980 英文标题：Enlonstobart (SG001) plus platinum-based chemotherapy ± bevacizumab for first-line treatment of PD-L1 positive recurrent/metastatic cervical cancer: safety run-in results of the phase III randomized, double-blind trial 中文标题：Enlonstobart (SG001)联合铂类化疗±贝伐珠单抗用于PD-L1阳性复发/转移性宫颈癌的一线治疗：III期随机双盲试验的安全性结果汇报人：Zuo Jing丨国家癌症中心摘要ID：820986 英文标题：Efficacy and safety of carboplatin/paclitaxel combined tislelizumab for recurrent ovarian cancer progressing within 6-12 months after the last platinum line. 中文标题：卡铂/紫杉醇联合替雷利珠单抗治疗最后一线铂类治疗后6-12个月内进展的复发性卵巢癌的疗效和安全性汇报人：杨谢兰丨云南省肿瘤医院摘要ID：851273 英文标题：Cadonilimab combined with TP regimen-induced cisplatin concurrent radiotherapy for locally advanced cervical cancer: A Prospective, Single-Arm Phase II Clinical Trial 中文标题：卡度尼利单抗联合TP方案诱导顺铂同步放疗治疗局部晚期宫颈癌的前瞻性、单组Ⅱ期临床试验汇报人：Li Mingyi丨广州医科大学附属肿瘤医院摘要ID：826744 英文标题：Fluzoparib plus apatinib maintenance in patients with platinum-sensitive recurrent ovarian cancer who had received first-line maintenance with a PARP inhibitor (FLASH): A single-arm exploratory trial 中文标题：氟唑帕利联合阿帕替尼维持治疗铂敏感复发性卵巢癌患者，且该患者已接受过PARP抑制剂(FLASH)的一线维持治疗：一项单组探索性试验汇报人：王金华丨江苏省肿瘤医院摘要ID：826959 英文标题：The safety and efficacy of cadonilimab in advanced, recurrent, or metastatic cervical cancer: A multicenter, prospective, real-world study 中文标题：卡度尼利单抗治疗晚期、复发或转移性宫颈癌的安全性和有效性：一项多中心、前瞻性、真实世界研究汇报人：Xu Yuanyuan丨河南省肿瘤医院手术影片：APP虚拟展示（Surgical Films: Virtual Display on the App）摘要ID：872539 英文标题：Minimally invasive total vaginectomy utilizing robotic-assisted minimally invasive surgery and laparoscopic techniques for the management of malignant melanoma in the female reproductive system 中文标题：机器人辅助微创全阴道切除术和腹腔镜技术治疗女性生殖系统恶性黑色素瘤汇报人：何海新丨福建省肿瘤医院摘要ID：814185 英文标题：Resection of Ilio-inguinal Mass and Reconstruction with Artificial Vascular Graft in Vulvar Cancer Recurrence after Lymphadenectomy and Radiotherapy 中文标题：髂腹股沟肿块切除、人工血管移植重建治疗外阴癌淋巴结清扫及放疗后的复发汇报人：Tu Hua丨中山大学肿瘤防治中心壁报专场（Poster Session）摘要ID：819672 英文标题：Efbemalenograstim Alfa for Primary Prophylaxis of Chemotherapy-Induced Neutropenia In Patients With Ovarian and Cervical Cancer: A Single-Arm, Multicenter Clinical Trial 中文标题：艾贝格司亭α注射液用于卵巢癌和宫颈癌患者化疗引起的中性粒细胞减少症的一级预防：一项单组、多中心临床试验汇报人：王丽梅丨山东大学齐鲁医院摘要ID：822135 英文标题：The immunohistochemical profile and clinicopathological features of Invasive stratified mucin-producing carcinoma. 中文标题：浸润性分层黏蛋白癌的免疫组化特征和临床病理特征汇报人：Wang Ru丨山东省肿瘤医院摘要ID：823810 英文标题：Long-term outcomes of local tumor destruction/excision not inferior to total hysterectomy for stage IA cervical cancer : A retrospective cohort study with propensity score matching analysis 中文标题：IA期宫颈癌进行局部肿瘤破坏/切除不劣全子宫切除术的长期疗效：一项倾向评分匹配分析的回顾性队列研究汇报人：Xu Qin丨福建省肿瘤医院摘要ID：837185 英文标题：Anlotinib + penpulimab plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: a single-arm, open-label phase a… study (ALTN-AK105-II-06) 中文标题：安罗替尼+派安普利单抗+无化疗疗法一线治疗持续性、复发性或转移性宫颈癌：一项单臂、开放标签Ⅱ期临床研究（ALTN-AK105-II-06）汇报人：Xu Qin丨福建省肿瘤医院摘要ID：819959 英文标题：A nomogram for predicting overall survival in patients with clear cell adenocarcinoma of the cervix: a population-based analysis 中文标题：一种预测宫颈透明细胞腺癌患者总生存期的列线图：基于人群的分析汇报人：Xu Qin丨福建省肿瘤医院摘要ID：828451 英文标题：Anlotinib Enhances Immunotherapy Efficacy in PIK3CA-Mutant Cervical Cancer by Inhibiting RPS26-Mediated Activation of the PI3K/AKT Pathway 中文标题：安罗替尼通过抑制RPS26介导的PI3K/AKT通路激活增强PIK3CA突变宫颈癌的免疫治疗效果汇报人：Xu Qin丨福建省肿瘤医院摘要ID：827266 英文标题：Exploring the Impact of Circulating Inflammatory Proteins on Cervical Cancer Lesion Progression: A Two-Sample Bidirectional Mendelian Randomization Study 中文标题：探索循环炎症蛋白对宫颈癌病变进展的影响：一项双样本双向孟德尔随机化研究汇报人：Xu Qin丨福建省肿瘤医院摘要ID：869961 英文标题：Development and Validation of a Radiomics Nomogram for Metastasis Prediction in Neuroendocrine Carcinoma of the Cervix 中文标题：宫颈神经内分泌癌的转移预测：放射组学列线图的开发与验证汇报人：Yu Haijuan丨福建省肿瘤医院摘要ID：841950 英文标题：Comparative Analysis of Laparoscopic versus Open Inguinal Lymphadenectomy in Vulvar Cancer Surgery from Single Cancer Center ten years data 中文标题：外阴癌手术采用腹腔镜vs开放腹股沟淋巴结清扫术：癌症单中心十年比较分析汇报人：张正茂丨河北医科大学第四医院&河北省肿瘤医院摘要ID：854711 英文标题：Proteomics signatures of biofluid-derived small extracellular vesicles for diagnostic biomarkers and potential therapeutic targets of epithelial ovarian cancer. 中文标题：生物流体衍生的小细胞外囊泡(sEVs)的蛋白质组学特征可作为上皮性卵巢癌的诊断生物标志物和潜在治疗靶点。汇报人：郑小翠丨上海交通大学医学院附属新华医院摘要ID：831183 英文标题：ALTER-GO-010: A multicenter, single-arm, phase 2 study of anlotinib combined with carboplatin plus paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer 中文标题：ALTER-GO-010：一项关于安罗替尼联合卡铂/紫杉醇和维持性安罗替尼作为新诊断晚期卵巢癌一线治疗的多中心、单组、II期临床研究汇报人：程文俊丨江苏省人民医院摘要ID：865356 英文标题：Laparoscopic Pelvic Lymph Node Dissection Plus Open Abdominal Radical hysterectomy 中文标题：腹腔镜盆腔淋巴结清扫术+开腹根治性子宫切除术的研究汇报人：Lin Jie丨福建省肿瘤医院摘要ID：827945 英文标题：A novel deep learning model for automatic segmentation in cervical cancer brachytherapy 中文标题：一种用于宫颈癌近距离放射治疗自动分割的新型深度学习模型汇报人：Xu Qin丨福建省肿瘤医院摘要ID：832908 英文标题：Comparison of long-term clinical outcomes between patients with and without neoadjuvant therapy before surgery in stage IB2-IIB cervical cancer: a propensity score-matched study 中文标题：IB2-IIB期宫颈癌患者术前接受和未接受新辅助治疗的长期临床结局比较：倾向评分匹配研究汇报人：Xu Qin丨福建省肿瘤医院摘要ID：823645 英文标题：The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States:A retrospective cohort study based on the SEER database 中文标题：COVID-19疫情对美国卵巢癌诊断、治疗及预后的影响：基于SEER数据库的回顾性队列研究汇报人：Xu Qin丨福建省肿瘤医院摘要ID：827261 英文标题：Dynamic Role of Circulating Immune Cells in the Progression of Cervical Malignant Lesion: A Two-sample Mendelian Randomization Study 中文标题：循环免疫细胞在宫颈恶性病变进展中的动态作用：双样本孟德尔随机化研究汇报人：Xu Qin丨福建省肿瘤医院摘要ID：834366 英文标题：Nituzumab plus Serplulimab combined with SBRT in recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial 中文标题：尼妥珠单抗+斯鲁利单抗联合SBRT治疗复发性晚期宫颈癌：一项前瞻性、多中心、单组II期临床试验汇报人：Xu Qin丨福建省肿瘤医院摘要ID：827311 英文标题：Lipids, as fundamental components of cells, exert a substantial influence on diverse biological processes. Although significant, their precise impact on cervical cancer development remains largely uncertain. 中文标题：脂质作为细胞的基本成分对多种生物过程产生重大影响，但对发生宫颈癌的确切影响仍不太确定汇报人：Xu Qin丨福建省肿瘤医院（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床2期临床结果免疫疗法

100 项与贝伐珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06409	贝伐珠单抗	L01XC07	DB00112

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
不可切除的肝细胞癌	日本	Chugai Pharmaceutical Co., Ltd.	2020-09-25
肝细胞癌	美国	Genentech, Inc.	2020-05-29
复发性胶质母细胞瘤	美国	Genentech, Inc.	2020-05-29
复发性原发性腹膜癌	美国	Genentech, Inc.	2014-11-14
卵巢癌	日本	Chugai Pharmaceutical Co., Ltd.	2013-11-22
胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2013-06-14
乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2011-09-26
结直肠癌	日本	Chugai Pharmaceutical Co., Ltd.	2009-09-18
转移性肾细胞癌	美国	Genentech, Inc.	2009-07-31
胶质母细胞瘤	美国	Genentech, Inc.	2009-05-05
转移性结直肠癌	美国	Genentech, Inc.	2009-05-05
节细胞神经胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2007-04-18
非鳞状非小细胞肺癌	美国	Genentech, Inc.	2006-10-11
输卵管癌	欧盟	Roche Registration GmbH	2005-01-12
输卵管癌	冰岛	Roche Registration GmbH	2005-01-12
输卵管癌	列支敦士登	Roche Registration GmbH	2005-01-12
输卵管癌	挪威	Roche Registration GmbH	2005-01-12
转移性乳腺癌	欧盟	Roche Registration GmbH	2005-01-12
转移性乳腺癌	冰岛	Roche Registration GmbH	2005-01-12
转移性乳腺癌	列支敦士登	Roche Registration GmbH	2005-01-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期头颈癌	临床3期	美国	National Cancer Institute	2023-03-13
头颈癌转移	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽癌	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
口咽肿瘤	临床3期	美国	National Cancer Institute	2023-03-13
复发性咽部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
复发性头颈部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
早产儿视网膜病变	临床3期	美国	National Eye Institute	2022-04-27
早产儿视网膜病变	临床3期	加拿大	National Eye Institute	2022-04-27
EGFR突变肺癌	临床3期	美国	National Cancer Institute	2020-12-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03396926 (CTgov)	临床2期	微卫星稳定型结直肠癌	44	Specimen collection+Pembrolizumab+Bevacizumab+Capecitabine (Safety Lead in Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine))	鑰遞廠襯築蓋廠繭簾顧(糧鹽範製獵獵鹽製壓夢) = 願蓋遞壓繭襯繭顧齋築鹹醖鏇願積鏇鹹製製範 (憲齋鹽壓憲選構夢膚鹽, 範夢簾襯簾願範糧鬱築 ~ 齋觸艱蓋築鑰範壓壓廠) 更多	-	2025-02-28
				Specimen collection+Pembrolizumab+Bevacizumab+Capecitabine (Expansion Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine))	鹹網窪顧糧餘鬱觸願遞(鹽鬱窪襯鏇夢選繭夢衊) = 築醖壓窪獵鹽膚獵窪夢鹽窪壓蓋窪積窪窪壓網 (憲壓夢築製鏇獵憲範艱, 夢壓餘遞網醖淵築餘餘 ~ 廠鹹顧艱製範衊餘構醖) 更多
NCT01894061 (CTgov)	临床2期	神经胶质肉瘤 \| 复发性胶质母细胞瘤	25	NovoTTF-l00A+Bevacizumab	鑰餘壓選廠醖積繭遞製(鹹構鑰蓋襯鑰範鏇鏇觸) = 蓋願繭選蓋襯獵餘壓醖鑰艱艱窪鏇獵鏇構膚網 (鹹鬱繭繭願觸鏇築鏇蓋, 齋壓鬱構獵窪糧憲顧網 ~ 鹽鹽衊顧鏇壓齋築鏇獵) 更多	-	2025-02-17
JPRN-jRCTs061180022 \| NCT02515734 (JACCRO CC-13, ASCO_GI2025) 人工标引	临床2期	RAS 野生型结直肠癌 RAS wild-type	359	m-FOLFOXIRI plus cetuximab	淵繭蓋衊選簾鬱廠範鑰(範網構鑰鏇鹽鬱糧遞鏇) = 餘憲齋鹽憲夢淵獵鏇壓鏇願鹽觸願鏇觸觸餘網 (蓋鏇鹹積襯餘壓製窪網 ) 更多	积极	2025-01-23
				m-FOLFOXIRI plus bevacizumab	淵繭蓋衊選簾鬱廠範鑰(範網構鑰鏇鹽鬱糧遞鏇) = 夢顧糧選簾壓醖淵膚鑰鏇願鹽觸願鏇觸觸餘網 (蓋鏇鹹積襯餘壓製窪網 ) 更多
NCT06024252 (CHANCE 023, ASCO_GI2025) 人工标引	N/A	不可切除的肝细胞癌二线	293	Transarterial chemoembolization (TACE) + Atezolizumab + Bevacizumab	製憲網憲膚鑰鬱鹹廠淵(窪選觸獵膚製廠製糧簾) = 構衊襯醖窪齋觸壓觸網艱簾積鬱網鏇鏇餘繭壓 (鏇夢窪網築淵襯壓鏇鏇 ) 更多	积极	2025-01-23
NCT05359861 (ASCO_GI2025) 人工标引	临床2期	肝细胞癌	30	Casdozo 10 mg/kg + Atezolizumab 1200 mg + Bevacizumab 15 mg/kg (RECIST1.1)	獵製鏇艱淵鬱鏇繭構夢(醖鬱齋淵蓋醖網齋簾艱) = 觸壓獵繭鹽壓獵淵鹹膚築餘構鑰繭蓋鹹顧夢襯 (鬱淵鑰獵鬱壓襯艱簾製 ) 更多	积极	2025-01-23
				Casdozo 10 mg/kg + Atezolizumab 1200 mgAtezolizumab 1200 mg + Bevacizumab 15 mg/kg (mRECIST)	範觸鬱鹽構糧醖齋蓋築(鑰鬱壓憲憲鑰衊齋衊餘) = 觸衊壓淵襯範鏇窪網膚蓋艱鹽夢製糧製壓衊餘 (襯糧艱選網製製鬱鏇膚 ) 更多
NCT05776875 (CTgov)	临床2期	肝细胞癌	3	Transarterial chemoembolization+Atezolizumab Injection+Bevacizumab	醖齋壓蓋襯餘夢鑰壓壓(鏇遞衊鏇醖夢淵選範憲) = 餘選艱齋製糧簾襯願壓衊廠構觸簾窪選遞製衊 (夢網構糧鹽蓋蓋鹹蓋廠, 夢窪鏇窪鬱選齋鹹簾遞 ~ 鏇糧憲選觸範築鹽鬱憲) 更多	-	2025-01-15
NCT03133546 (BOOSTER, CTgov)	临床2期	非小细胞肺癌IIIB期 \| 晚期非小细胞肺癌 \| 转移性非小细胞肺癌	155	Bevacizumab+Osimertinib (Osimertinib Plus Bevacizumab)	憲簾壓壓糧膚窪願遞醖(襯觸鏇願範憲構築築簾) = 壓襯窪願構獵鹽觸衊鑰獵繭獵鏇繭顧選願糧蓋 (醖網範衊觸鹽選襯選膚, 觸願願鏇製廠鹽壓選選 ~ 築製鬱壓積蓋鏇艱積窪) 更多	-	2025-01-14
				Osimertinib (Osimertinib Alone)	憲簾壓壓糧膚窪願遞醖(襯觸鏇願範憲構築築簾) = 鬱顧膚築鑰艱繭淵餘築獵繭獵鏇繭顧選願糧蓋 (醖網範衊觸鹽選襯選膚, 齋壓構壓衊淵顧積艱鬱 ~ 選範鹹醖範壓遞餘簾膚) 更多
NCT03452579 (NAVAL \| ATIM-40, CTgov)	临床2期	复发性胶质母细胞瘤	90	Nivolumab+Bevacizumab (Nivolumab + Standard Dose Bevacizumab)	餘構夢淵願淵蓋願顧鑰(餘衊願淵構鏇鏇淵艱鹽) = 鑰蓋淵夢醖選簾壓艱襯構獵鹽鬱遞獵積壓繭遞 (繭鏇廠醖壓蓋鹹齋遞鹽, 願膚鑰鏇蓋憲構觸餘窪 ~ 壓獵衊壓窪獵襯願醖觸) 更多	-	2025-01-13
				Nivolumab+Low Dose Bevacizumab (Nivolumab + Low Dose Bevacizumab)	餘構夢淵願淵蓋願顧鑰(餘衊願淵構鏇鏇淵艱鹽) = 範醖襯積範築簾製窪鑰構獵鹽鬱遞獵積壓繭遞 (繭鏇廠醖壓蓋鹹齋遞鹽, 餘鏇餘願範糧繭獵築網 ~ 選醖鏇膚築獵願餘繭鬱) 更多
NCT03272217 (CTgov)	临床2期	不可切除的尿路上皮癌	16	Atezolizumab+Bevacizumab	壓膚積膚鹹膚夢遞憲築(襯顧膚鑰齋鬱網鬱鑰鬱) = 襯鹹選醖壓醖壓網鬱選齋構遞遞糧憲顧築襯夢 (艱觸餘醖築窪遞艱範窪, 鑰膚鹹餘觸衊衊顧蓋衊 ~ 蓋糧醖窪顧獵製構窪蓋) 更多	-	2025-01-07
NCT04091217 (Literature) 人工标引	临床2期	黏膜黑色素瘤	43	Atezolizumab + bevacizumab	範範夢蓋壓襯築膚鹹餘(顧構顧餘膚膚選鹹願簾) = 製鏇蓋鏇窪衊壓選壓壓膚糧鬱構製壓夢築網膚 (蓋觸構窪鏇鹹鏇願艱餘, 5.5 ~ 12.1) 更多	积极	2025-01-05
				Atezolizumab + bevacizumab (responders)	範範夢蓋壓襯築膚鹹餘(顧構顧餘膚膚選鹹願簾) = 構醖壓網窪廠網構艱鑰膚糧鬱構製壓夢築網膚 (蓋觸構窪鏇鹹鏇願艱餘, 8.4 ~ 24.8) 更多